Document Detail

Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang.
MedLine Citation:
PMID:  22626453     Owner:  NLM     Status:  Publisher    
Molecular minimal residual disease (MRD) analysis is fast emerging as an essential clinical decision-making tool for the treatment and follow-up of mature B cell malignancies. Current EuroMRD consensus IGH real-time quantitative polymerase chain reaction RQ-PCR assays rely on flow cytometric assessment of diagnostic tumour burdens to construct 'normalized', patient-specific, diagnostic DNA-based MRD quantification standards. Here, we propose a new 'hybrid' assay that relies on plasmid-based quantification of patient-specific IGH VDJ targets by consensus IGH real time (RQ)-PCR, combined with EuroMRD guidelines, for MRD monitoring in lymphoid malignancies. This assay was evaluated for MRD assessment in a total of 273 samples from 29 mantle cell lymphoma (MCL) patients treated within a Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang (GOELAMS) Phase II trial and was feasible, reliable and consistently comparable to gold-standard MRD techniques (99% concordance across all samples including 32 samples within the quantitative range) when analysed in parallel (117 samples). Integrating clinical prognostic parameters and MRD status in peripheral blood at the post-induction stage was predictive of progression-free survival (P = 0·034) thus demonstrating the clinical utility of the approach. Plasmid-based standards for the quantification of IGH VDJ targets are therefore confirmed to offer new opportunities for further standardization and clinical evaluation of MRD-guided management of patients with mature B cell malignancies.
Estelle Gimenez; Martine Chauvet; Laetitia Rabin; Isabelle Puteaud; Samuel Duley; Sieme Hamaidia; Juliana Bruder; Valérie Rolland-Neyret; Steven Le Gouill; Olivier Tournilhac; Eric Voog; Hervé Maisonneuve; Marie C Jacob; Dominique Leroux; Marie C Béné; Christine Formisano-Tréziny; Jean Gabert; Rémy Gressin; Mary B Callanan
Related Documents :
22914983 - A high positive lymph node ratio is associated with distant recurrence after surgical r...
22562583 - Side effects in melanoma patients receiving adjuvant interferon alfa-2b therapy: a nurs...
20030683 - A single-center retrospective analysis of liver transplantation on 255 patients with he...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-5-25
Journal Detail:
Title:  British journal of haematology     Volume:  -     ISSN:  1365-2141     ISO Abbreviation:  -     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-5-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372544     Medline TA:  Br J Haematol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2012 Blackwell Publishing Ltd.
INSERM U823, Institut Albert Bonniot, Grenoble, France; Université Joseph Fourier-Grenoble I, Institut Albert Bonniot, Grenoble, France; Plateforme de génétique moléculaire des cancers, Pôle de Biologie, CHU de Grenoble, Grenoble, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Multicenter Case-Control Study of Risk Factors for Cutaneous Melanoma in Valencia, Spain.
Next Document:  Surgical management of extracranial carotid artery aneurysm.